

参术胶囊对脾虚胃癌小鼠ERK信号通路中AP-1和IL-2的影响

投稿时间： 2011-12-31 点此下载全文

引用本文： 邓青秀,彭成,敖慧,谢晓芳.参术胶囊对脾虚胃癌小鼠ERK信号通路中AP-1和IL-2的影响[J].中国实验方剂学杂志,2012,18(10):177~182

摘要点击次数：**154**

全文下载次数：**48**

作者 单位

E-mail

邓青秀 成都中医药大学, 成都 610075
彭成 成都中医药大学, 成都 610075
敖慧 成都中医药大学, 成都 610075
谢晓芳 成都中医药大学, 成都 610075

pengchengcao@163.com

基金项目:国家"十五"科技攻关项目(2001BA701A-07-19)

中文摘要:目的:研究参术胶囊对脾虚胃癌小鼠细胞外调节蛋白激酶(ERK)信号通路中转录激活蛋白-1(AP-1)和白细胞介素-2(IL-2)的影响,以探讨参术胶囊阻断脾虚胃癌发生的机制。方法:随机取17只SPF小鼠作为空白组正常喂养,其余小鼠均首日给予山西白醋 $15\text{ mL}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ 灌胃,次日给予 $10\text{ mL}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ 灌胃,连续9 d,第10天给予N-亚硝基二乙胺(DENA)按 $2.8\text{ mg}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ 灌胃,连续110 d,建立脾虚胃癌小鼠模型。将模型动物随机分为模型组、胃复春片 $718\text{ mg}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ 剂量组、参术胶囊 $440,220,110\text{ mg}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ 剂量组,试验组从111 d起灌胃给药,连续30 d。实验结束后,观察各组小鼠一般情况的变化;HE染色观察参术胶囊是否阻断脾虚胃癌的发生;用免疫组化法研究参术胶囊对诱导脾虚胃癌模型ERK1/2,AP-1,IL-2等指标的影响。结果:参术胶囊作用脾虚胃癌小鼠模型30 d后,能改善诱发型脾虚胃癌小鼠模型一般状态,其病理表现较模型组明显减轻,免疫组化结果显示胃复春片组和参术胶囊 $440,220\text{ mg}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ 剂量组均能明显增强模型动物ERK1/2,AP-1,IL-2的表达($P<0.05,P<0.01$),参术胶囊 $110\text{ mg}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ 剂量组能明显增强模型动物ERK1/2的表达($P<0.01$),而对AP-1,IL-2的表达无明显改善。结论:参术胶囊可通过ERK信号通路阻断脾虚胃癌发生。

中文关键词:[ERK信号通路](#) [参术胶囊](#) [脾虚](#) [胃癌](#)



The Effect of Shenzhu Capsules on AP-1 and IL-2 of ERK Signal Pathway in Gastric Cancer Mice with Spleen-deficiency

Abstract:Objective: To study the effect of Shenzhu capsules on AP-1 and IL-2 of ERK signal pathway in the gastric cancer mice with spleen-deficiency and explore the molecular mechanism of Shenzhu Capsules in inhibiting the generation of gastric cancer mice with spleen-deficiency. Method: Seventeen mice were randomly selected as normal group. The other mice were administrated by $15\text{ mL}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ Shanxi white venigar on the first day and $10\text{ mL}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ from the second day for continuous 9 days and by $2.8\text{ mg}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ diethylnitrosamine(DENA) for 110 days to establish gastric cancer mice model with spleen-deficiency.The model mice were divided into model group, Weifuchun group, and 3 doses of Shenzhu capsules groups($440, 220$ and $110\text{ mg}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$). The mice of treatmental groups were administrated on the 111th day and for continuous 30 days. The general state of animals were observed,the HE staining was used to study whether Shenzhu capsules inhibited the occurrence of gastric cancer with spleen-deficiency and the immunohistochemistry method was used to study the influence of Shenzhu capsules on the ERK1/2,AP-1 and IL-2 expression when the experiment was over. Result: The general state and pathological manifestation of Shenzhu capsule groups mice was improved obviously compared with that of model group ones. The Weifuchun and the $440, 220\text{ mg}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ Shenzhu capsules could obviously strengthen expression of ERK1/2,AP-1 and IL-2($P<0.05,P<0.01$). $110\text{ mg}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ Shenzhu capsules could obviously strengthen the expression of ERK1/2($P<0.01$) but not obviously strengthen the expression of AP-1 and IL-2. Conclusion: Shenzhu capsules can inhibit the occurrence of gastric cancer with spleen-deficiency by inactivating ERK signal pathway.

keywords:[ERK signal pathway](#) [Shenzhu capsules](#) [spleen-deficiency](#) [gastric cancer](#)

[查看全文](#) [查看/发表评论](#) [下载PDF阅读器](#)

广告服务





中国实验方剂学杂志编辑部版权所有
您是本站第**3042375**位访问者 今日一共访问**2975**次 linezing.com
地址：北京东直门内南小街16号 邮编：100700
电话：010-84076882 在线咨询 [京ICP备09084417号](http://www.beian.gov.cn/portal/registerSystemInfo?recordId=09084417&recordType=0)